391 related articles for article (PubMed ID: 18927310)
1. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.
Finke JH; Rini B; Ireland J; Rayman P; Richmond A; Golshayan A; Wood L; Elson P; Garcia J; Dreicer R; Bukowski R
Clin Cancer Res; 2008 Oct; 14(20):6674-82. PubMed ID: 18927310
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
Ko JS; Zea AH; Rini BI; Ireland JL; Elson P; Cohen P; Golshayan A; Rayman PA; Wood L; Garcia J; Dreicer R; Bukowski R; Finke JH
Clin Cancer Res; 2009 Mar; 15(6):2148-57. PubMed ID: 19276286
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
Flörcken A; Takvorian A; Van Lessen A; Singh A; Hopfenmüller W; Dörken B; Pezzutto A; Westermann J
Anticancer Drugs; 2012 Mar; 23(3):298-302. PubMed ID: 22156795
[TBL] [Abstract][Full Text] [Related]
4. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Whiteside TL; Furuya N
Head Neck; 2007 Feb; 29(2):120-7. PubMed ID: 17103408
[TBL] [Abstract][Full Text] [Related]
5. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
[TBL] [Abstract][Full Text] [Related]
6. An assessment of the immunological status of patients with renal cell carcinoma based on the relative abundance of T-helper 1- and -2 cytokine-producing CD4+ cells in peripheral blood.
Onishi T; Ohishi Y; Goto H; Tomita M; Abe K
BJU Int; 2001 Jun; 87(9):755-9. PubMed ID: 11412209
[TBL] [Abstract][Full Text] [Related]
7. [Effect of Sunitinib therapy on immune function of patients with advanced renal cell carcinoma].
Xian P; Li Y; Zhou H; Luo H; Liu N; Dai JY
Zhonghua Wai Ke Za Zhi; 2016 Oct; 54(10):741-745. PubMed ID: 27686636
[No Abstract] [Full Text] [Related]
8. Regulatory T cells limit induction of protective immunity and promote immune pathology following intestinal helminth infection.
Sawant DV; Gravano DM; Vogel P; Giacomin P; Artis D; Vignali DA
J Immunol; 2014 Mar; 192(6):2904-12. PubMed ID: 24532574
[TBL] [Abstract][Full Text] [Related]
9. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
Zhao Q; Guo J; Wang G; Chu Y; Hu X
Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489
[TBL] [Abstract][Full Text] [Related]
10. Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
Mulder SF; Jacobs JF; Olde Nordkamp MA; Galama JM; Desar IM; Torensma R; Teerenstra S; Mulders PF; Vissers KC; Punt CJ; de Vries IJ; van Herpen CM
Clin Cancer Res; 2011 Jul; 17(13):4541-9. PubMed ID: 21712444
[TBL] [Abstract][Full Text] [Related]
11. Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma.
Fukuda H; Kondo T; Iida S; Takagi T; Tanabe K
Urol Oncol; 2016 Aug; 34(8):338.e1-9. PubMed ID: 27085488
[TBL] [Abstract][Full Text] [Related]
12. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients.
Adotevi O; Pere H; Ravel P; Haicheur N; Badoual C; Merillon N; Medioni J; Peyrard S; Roncelin S; Verkarre V; Mejean A; Fridman WH; Oudard S; Tartour E
J Immunother; 2010; 33(9):991-8. PubMed ID: 20948437
[TBL] [Abstract][Full Text] [Related]
13. CD4+CD25+Foxp3+ T regulatory cells, Th1 (CCR5, IL-2, IFN-γ) and Th2 (CCR4, IL-4, Il-13) type chemokine receptors and intracellular cytokines in children with common variable immunodeficiency.
Kutukculer N; Azarsiz E; Aksu G; Karaca NE
Int J Immunopathol Pharmacol; 2016 Jun; 29(2):241-51. PubMed ID: 26684629
[TBL] [Abstract][Full Text] [Related]
14. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy.
Kobayashi M; Kubo T; Komatsu K; Fujisaki A; Terauchi F; Natsui S; Nukui A; Kurokawa S; Morita T
Med Oncol; 2013 Jun; 30(2):556. PubMed ID: 23539200
[TBL] [Abstract][Full Text] [Related]
15. Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.
Noé G; Bellesoeur A; Thomas-Schoemann A; Rangarajan S; Naji F; Puszkiel A; Huillard O; Saidu N; Golmard L; Alexandre J; Goldwasser F; Blanchet B; Vidal M
Oncotarget; 2016 Oct; 7(41):67507-67520. PubMed ID: 27589830
[TBL] [Abstract][Full Text] [Related]
16. Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
Rautiola J; Lampinen A; Mirtti T; Ristimäki A; Joensuu H; Bono P; Saharinen P
PLoS One; 2016; 11(4):e0153745. PubMed ID: 27100185
[TBL] [Abstract][Full Text] [Related]
17. Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cells.
Busse A; Asemissen A; Nonnenmacher A; Ochsenreither S; Fusi A; Braun F; Stather D; Schmittel A; Miller K; Thiel E; Keilholz U
J Immunother; 2011 Jan; 34(1):113-9. PubMed ID: 21150720
[TBL] [Abstract][Full Text] [Related]
18. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
20. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
